# VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

> **NCT07052422** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 160 (estimated)

## Conditions studied

- Older Patients
- Myeloid Malignancies
- Conditioning
- Hematopoietic Stem Cell Transplantation (HSCT)

## Interventions

- **DRUG:** Venetoclax (VEN)
- **DRUG:** Decitabine (DAC)
- **DRUG:** Busulfan (Bu)
- **DRUG:** Fludarabine (Flu)
- **DRUG:** Fludarabine (Flu)

## Key facts

- **NCT ID:** NCT07052422
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07052422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07052422, "VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07052422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*